Discounted Cash Flow (DCF) Analysis Unlevered

Bellerophon Therapeutics, Inc. (BLPH)

$1.05

-0.06 (-4.98%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.05 | undervalue

Operating Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.05
Beta -0.076
Diluted Shares Outstanding 9.50
Cost of Debt
Tax Rate 100.00
After-tax Cost of Debt 0.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.337
Total Debt 0.95
Total Equity 9.98
Total Capital 10.93
Debt Weighting 8.74
Equity Weighting 91.26
Wacc

Build Up Free Cash

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 53.96%53.96%53.96%7.91%100.00%53.96%53.96%53.96%53.96%53.96%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure ----------
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.05
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -23.78
Equity Value -
Shares Outstanding 9.50
Equity Value Per Share -